Forms 8-K

30.01.2012

Company News

European Patent Office intends to grant Sangui wound dressing patent

Witten, Germany, January 30, 2012 - The European Patent Office has officially expressed its intention to grant a patent based on Sangui's application "Therapeutically Active Wound Dressings, Production thereof, and Use of the same". The publication of the grant is only subject to Sangui filing the requested additional translations into other official European languages. These translations are currently under way. The projected duration of the patent will not expire prior to 2024.

Wound dressings serve to safeguard the wound with its highly sensitive new granulation tissue from mechanical damage as well as from infection. Using the natural polymer chitosan derived from crab shells, Sangui's Chitoskin wound dressings show outstanding properties in supporting wound healing. The Chitoskin wound dressing shows excellent results in securing a moist wound climate while stimulating cell growth and serving as a cell matrix. Being the only foam based on natural, organic raw material it also has antibacterial properties.

25.01.2012

Company News

European Patent Office intends to grant Sangui key oxygen carrier patent

Witten, Germany, January 25, 2012 - The European Patent Office has officially expressed its intention to grant a patent based on Sangui's application (01 945 245) "Mammalian hemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof". The publication of the grant is only subject to Sangui filing the requested additional translations into other official European languages. These translations are currently being carried out. The projected duration of the patent will not expire prior to 2020. There is an option to have the duration extended for another five years. Sangui already holds a granted US patent on the basis of the same application.

The process protected by this patent is one of the cornerstones of Sangui's concept of artificial oxygen carriers. The so called pegylation (coating with polyethylene glycol) of the hemoglobin hyperpolymers serves several purposes, most important of which are a reduced immune reaction as well as minimized extravasations, increasing the intravascular persistence of the carrier in the blood and reducing a pharmacological vasoconstriction.

Key properties of artificial oxygen carriers include life saving oxygen supply to the heart or brain in cases of heart attack or stroke. As compared to other means of induced oxygen transport, Sangui's artificial oxygen carriers are expected to have additional advantages: simple storage, long shelf-life, they are blood group independent, free from infectious agents (viruses), and will be permanently available in sufficient quantities.

12.12.2011

Company News

Mexican State of Tamaulipas starts training doctors in Sangui wound management

Sangui enters commercialization phase / Initial order of Sangui developed wound spray

Witten, Germany, December 12, 2011

The Mexican State of Tamaulipas has issued an initial order of Hemo2Spray, the Sangui developed wound spray, as well as of the wound debridement product Scabremove both registered by the Mexican authorities in September this year. This is the first regular commercial order of the wound spray and Sangui management is positive that an era of innovative product development, testing and authorization will now come to fruition.

The medical product will initially be used in three state owned hospitals. While it will serve to treat patients suffering from chronic wounds its use in actual treatments will particularly be part of a comprehensive training program for doctors from other locations in Tamaulipas. The State health authorities have expressed their intent to apply the Sangui developed wound therapy in the 22 hospitals under their direction and start now in cooperation with Sangui medical staff to instruct and train their medical personnel. Global licensee SastoMed GmbH which is in charge of wound management operations expects that demand for the product will ramp up quickly when experienced doctors start treating patients throughout the state and as other Mexican states follow suit. Invoicing is to occur at short notice while shipment of the product is scheduled for early January 2012.

19.09.2011

Company News

Mexico authorizes use of Sangui developed wound management system

Official registration as medical device granted / State of Tamaulipas indicates plans to start treatment in 22 hospitals

Witten, Germany, September 19, 2011

The Mexican Commission for the Authorization of Pharmaceuticals and Medical Devices officially registered the entire current range of Sangui developed wound management products as medical devices and granted permission to use this treatment on a nationwide basis.

In the meantime the Secretaria de Salud (Secretary of Health) of the Mexican State of Tamaulipas as a first legal entity in Mexico indicated in an official letter that it has the firm intention to actually apply the Sangui developed wound therapy in the 22 hospitals under its direction. It is to be recommended as the state of the art treatment of chronic wounds in the indications of leg ulcer and diabetic foot. An exact starting date for this program has not been fixed yet. SanguiBioTech GmbH and SastoMed GmbH as global licensee are ready to jointly enter negotiations about the terms of trade with customers in Mexico and beyond. It is being assumed that the official registration in Mexico may serve as a door opener for respective registrations in other Central American countries.

This is the first official authorization to use and distribute the Sangui developed wound treatment. Comprehensive clinical test treatments had been carried out in 2009 at the Hospital Civil in Ciudad Victoria, capital of the Mexican state of Tamaulipas. The tests were concluded successfully. In the course of the treatments the control group had been closed and patients shifted to the Sangui developed therapy for ethical reasons. In the event the total healing ratio was significantly higher than 75%.

The results were evaluated by the State Health Authorities of Tamaulipas and presented to the Mexican Federal Health Authorities as well as on the occasion of international dermatological and wound management congresses. The certification process in compliance with Mexican and international standards was carried out professionally by the staff and consultants of Sangui Latin America SA, the legally non-related local partners of Sangui BioTech International, Inc. in Mexico.

Eduardo Martinez Mena, CEO of Sangui Latin America SA, emphasized: "In close cooperation with our German partners we invested a considerable amount of time, money and diligence in this project over the past five years. We are more than glad that our continued efforts now have come to fruition and very excited about the huge opportunities this authorization will offer for the patients as well as for our company."

Sangui BioTech International, Inc., Director Hubertus Schmelz congratulated: "Our Mexican partners have attained the first manifest breakthrough for our products - and hence for Sangui as a whole. The Mexican authorization is the seal and first official confirmation of their therapeutic properties, and is the logic result of the studies conducted by the Tamaulipas Health Authorities. The certification processes worldwide are designed to protect the patients and, therefore, extensive, detailed and time consuming. But this event now shows that our joint professional and diligent approach is the right and only way to reach our business objectives."

Michael Sander, Managing Director of SastoMed, explained: "We are proud to find that the Mexican authorities are leading the way to give patients access to our novel and promising treatment of chronic wounds. To a considerable extent, the smooth registration process in Mexico was due to the comprehensive work we carried out to gain convincing data to prove the safeness and efficacy of the treatment. As authorities' demands regarding medical devices are broadly comparable we confirm our ambitious schedule towards an EU registration as the next step to a global market entry."

All parties agreed that their cooperation over the years has proved to be successful, resting solidly on their common trust in the properties of this unique wound healing therapy. Both SastoMed and Sangui underlined that the German side is ready to enter negotiations about terms and deliveries and is currently initiating the necessary preparations to have the products manufactured in the required qualities and quantities.

Mexican health authorities lay special emphasis on their continued efforts to abate the consequences of lifestyle diseases such as diabetes. Estimates indicate that more than 40% of the Mexican population suffers from venous diseases. Currently, there are 17 million identified diabetics in Mexico, this being the second largest diabetes rate in the world. In Mexico more than $30 bn per year are being spent on diabetics' treatments. It is being expected that the consistent use of the Sangui developed wound treatment will help to significantly reduce the costs in this particular sector.

20.12.2010

Company News

SanguiBioTech and SanderStrothmann Establish Joint Venture

Sangui Sells Hemospray Marketing and Sales License to New Company

Witten, Germany, December 20, 2010 -
SanguiBioTech GmbH, Witten, Germany, and SanderStrothmann GmbH, Georgsmarienhuette, Germany, have established a joint venture company under the name of sastOmed GmbH. The respective agreements and articles were now signed, and recorded by a notary.

It is the purpose of the new company to obtain the CE mark certification of the Hemospray wound spray and to start producing, marketing and distributing the product on a global scale. To this effect, Sangui has granted sastOmed GmbH comprehensive and exclusive licenses on a global scale. Project management, financing and execution of the projected activities will be taken care of by the joint venture which will be headed by Michael Sander and Rene Strothmann, Managing Directors of SanderStrothmann GmbH, who in addition will contribute their experience in product development and their proven industry contacts and cooperations.

Under the terms of the contracts sastOmed will pay a milestone-based downpayment as compensation for the licenses and has granted Sangui royalties on all future sales of the product. The parties agreed not to disclose any further details of the agreements and articles.

Hubertus Schmelz, Managing Director of SanguiBioTech GmbH emphasized: "Since 2004, it was one of our key strategic goals to cooperate with an industry partner with the financial and operating power and expertise to successfully develop, promote, and market our key products. The joint venture and licensing agreement is a decisive breakthrough on our way to reaching our goals." SanguiBioTech GmbH will now be in the position to focus on its other cosmetics and wound management products as well as on long term projects such as the artificial oxygen carrier.

11.10.2010

Company News

Sangui Sangui and SanderStrothmann look at Joint Venture for HEMO2SPRAY Certification and Marketing

Agreement signed to consolidate close cooperation and partnership

Witten, Germany, October 11, 2010 - SanguiBioTech GmbH, Witten, Germany, and SanderStrothmann GmbH, Georgsmarienhuette, Germany, have signed a binding agreement to establish a joint venture at short notice. The parties came to this agreement in view of the promising course the individual treatments have taken, which are currently being continued at the Department of Dermatology of Charles University in Prague under the direction of Prof. Dr. Petr Arenberger, President of the Czech Society of Dermatology and Venereology and Honorary Member of the German Dermatologic Society (DDG).

Sole purpose of the new company will be to obtain the CE mark certification of the HEMO2SPRAY wound spray and start marketing the product on a global scale. Sangui will contribute the pertinent licenses and knowhow on an exclusive basis while SanderStrothmann will finance the steps to finalize the certification process including the establishing and validation of production facilities, obtaining additional clinical data as well as initial marketing efforts. Project management and execution of the projected activities will be taken care of by the joint venture which will be headed by Michael Sander, Managing Director of SanderStrothmann GmbH. The future dividends of this Ltd. Company will be shared on a flexible scale taking into account the contributions of each party. In any event, Sangui GmbH will receive the larger part. In addition, SanderStrothmann GmbH is to acquire a small share of Sangui BioTech International, Inc., stock to underline the close cooperation and partnership between the two companies.

Michael Sander, Managing Director of SanderStrothmann GmbH, pointed out: "We have seen that the claims of this product are justified and we are convinced that jointly we are looking at a huge market potential. We will combine forces in order to pursue a joint professional approach and accelerate the processes leading to the certification and subsequent market entry of the product. Sangui's innovation and expertise will serve as an excellent basis for future medical and economic success."

"SanderStrothmann have an impressive track record of successfully launching products and leading them from the concept phase to market success. For a couple of months now our cooperation has intensified on the basis of a sound mutual understanding and esteem. We are proud that today we have been able to underpin this partnership with a firm long-term perspective which will enable us to finalize the HEMO2SPRAY certification faster than before and to move straight on to an international market entry", Sangui BioTech Director Hubertus Schmelz added.

15.06.2010

Company News

Sangui and SanderStrothmann cooperate in the wound management sector
Expert opinion confirms effectiveness of Sangui system, requests more details about stand alone properties of Hemospray

Witten, Germany, June 15, 2010 - SanguiBioTech GmbH received an expert opinion as produced on behalf of the Notified Body in charge of the certification of Sangui's HEMO2SPRAY wound spray. In this document the expert, one of Germany's leading clinical wound care specialists, underlines the "excellent healing ratios of >90%" and confirms that the Sangui wound healing system consisting of debridement, cleaning, wound spray and wound dressing "obviously has to be regarded as significant". According to his opinion, however, the Tamaulipas study design did not permit a specific judgment with regard to the stand alone properties of HEMO2SPRAY.

In order to proceed with the certification process, SanguiBioTech GmbH intends to prepare a series of additional test treatments specifically designed to demonstrate the isolated effect of HEMO2SPRAY on wound healing. To this effect, the company will cooperate with SanderStrothmann GmbH, a company with an international track record in both, cosmetics and health care research, product development and marketing. SanderStrothmann already are identifying appropriate hospitals, where the treatments are to be carried out. In the pursuit of the cooperation Sangui will contribute intellectual, medical and product support and participate in setting up the joint treatment design while SanderStrothmann will oversee the entire process and assist in securing the financing of the project. Moreover, SanderStrothmann are cooperating with a renowned international health care group which has demonstrated significant interest in including HEMO2SPRAY in their product portfolio as soon as the CE mark will have been granted. As of now, no contracts were signed in this regard.

10.11.2009

Company News

Mexican Health Authorities Present Sangui Wound Healing System at International Convention

Witten, Germany, November 10, 2009 - Dr. Javier Garcia Luna, Chief Investigator of the recently accomplished comparative wound healing study carried out in Cd. Victoria, Tamaulipas, Mexico, presented its results in front of numerous representatives of Latin American Health Authorities.

The study of two groups of patients, one being treated with conventional methods, the other one using the Sangui wound healing Hemospray had "clearly shown HEMO2SPRAY to be vastly superior in therapeutic efficiency", as the official report concludes. Setting the scene for this lecture was the annual congress "Foro Nacional de Tecnologias para la Salud" organized by the "Centro Nacional de Excelencia Tecnologica en Salud" in Mexico City (National Centre for Technological Excellence in the Health Sector), the most important international event of its kind in Central America. Only a few out of hundreds of abstracts submitted are invited to a fully fledged presentation in one of the forums.

Sangui Latin America SA de CV und Sangui BioTech are enthusiastic about the outcome of the study and extend their gratitude to the doctors and medical staff on location who carried out this study according to leading edge professional standards. Excerpts from Dr. Luna's presentation who also serves as a high ranking official of the Tamaulipas Ministry of Health are now available on the corporate website www.sangui.de.

29.10.2009

Company News

Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded

Results Confirm Unique Properties of Hemospray

Witten, Germany, - October 29, 2009

The comparative study of chronic wound treatment at the Hospital Civil of Cd. Victoria, Tamaulipas, Mexico, was concluded successfully. Due to the significantly superior therapeutic success the Ministry of Health ordered the control to be abandoned and moved to HEMO2SPRAY treatment for ethical reasons. 22 of the 24 patients within the HEMO2SPRAY group were healed completely, while 22 of the 24 patients of the control group showed no comparable progress. Moreover, additional patients suffering from diabetic foot disease were successfully treated with Hemospray. The total healing ratio is significantly higher than 75%.

These results were presented to health system representatives of several Latin American countries in Mexico City by the Chief Investigator of the study.

The results are currently being evaluated by the State Health Authorities of Tamaulipas who sponsored the study.

Apart from this, a considerable share of the patient data were crosschecked and evaluated by Sangui in Witten. It turned out that these data confirm the results as previously indicated. Sangui regards this outcome as a confirmation of the outstanding efforts made by the teams on location and as a great success of its systematic competence in wound healing.

09.02.2009

Company News

Telephone sales boost Sangui's cosmetic business, new prospects

Witten, Germany, February 9, 2009 - Telephone sales activities dedicated to specialized resellers like beauty and wellness parlors initiated in December 2009 have begun boosting SanguiBioTech's cosmetics business. Several hundreds of beauty parlors requested and received an information package. As many as 175 cosmetic experts underpinned their interest to offer PureMoisture to their clients by purchasing a two product PureMoisture starter set. Given the fact that sales were interrupted for the holiday season, this is an extraordinary result, experts say. An increasing part of the new customers has started ordering additional quantities. The telephone marketing provider and staff rely on a database of proven addresses and were given extensive trainings by Sangui marketing. Another row of additional addresses will be contacted over the next couple of weeks.

In view of the promising results in Germany contacts will be established to reliable telephone marketing providers on an international scale. New contacts to selected key media may eventually increase public awareness (also for the PureMoisture web shop) and help create additional demand.

Moreover, test quantities were provided to one large US cosmetics retailer as well as to a large shipping company operating a fleet of cruisers in the Caribbean planning to offer their passengers wellness treatments based on PureMoisture during the next cruise of their flagship.

To a considerable extent, these activities originate from the cooperation between SanguiBioTech GmbH and Fanales GmbH announced in October 2008. Fanales Managing Director Hans Wollmann explains: "Cosmetics is one of the toughest markets around. But Sangui has a revolutionary concept which needs special promotion apart from the trodden paths of mainstream body and face care." - "After having gained a deeper insight into the industry, we find that the personal introduction of an innovative concept to experts who are willing to become our resellers simply yields better results than any previous attempt"; Hubertus Schmelz, Managing Director of Sangui GmbH adds.

19.12.2008

Company News

Sangui shareholders elect directors, authorize capital

Witten, Germany, December 19, 2008 - The general meeting of shareholders of Sangui BioTech International, Inc., has resolved upon the proposals as submitted by the board of directors. Participating were 50.7% of the total of 50,000,000 shares issued and outstanding. The meeting which had taken place on November 18, 2008 had been adjourned to December 16, 2008 in order to permit additional shareholders to submit their votes.

The Board of Directors now consists of Joachim Fleing, Hubertus Schmelz and Thomas Striepe. Over 97% of votes were cast in favor of these nominees. The amended and restated Articles of Incorporation of the company were approved by 71.4% of votes. The remaining proposals all obtained a majority of above 70% and are thereby approved and ratified.

11.12.2008

Company News

State of Tamaulipas (Mexico) starts clinical study involving Sangui wound management system

Witten, Germany, December 11, 2008 – Sanguis BioTech Latino América and the Servicios de Salud de Tamaulipas, the Mexican State of Tamaulipas Health Authority have started a clinical study regarding the treatment of chronic wounds at the Civil Hospital "Dr. José Macia Hernadez" in Ciudad Victoria, the capital of Tamaulipas. According to an agreement signed to this effect December 4, 2008, a total of 80 patients suffering from chronic wounds will be treated competitively in groups of 40 patients each either according to the classic medical wound therapies or according to the wound management system as developed by SanguiBioTech. Signing the contract on behalf of the State of Tamaulipas were the Minister of Health Sr. Dr. Rodolfo Torre Cantu, the Under Secretary of State Sr. Amerigo Villareal Anaya, as well as the Managing Director of the Hospital Sr. Dr. Jesus Flores Robles.

Mexico is suffering from the second largest diabetes rate in the world, spending more than US $ 30.000.000.000 per year to fight its dire consequences. A special area of the Hospital Dr. Hernadez has been dedicated to those treatments, and special equipment for measurements, evaluation and supervision was installed. Results of the treatments will be measured against a joint medical protocol. The treatments were started immediately; initial results are expected to be available by the end of the first quarter of 2009.

On the occasion of the signing of the contract representatives of the Tamaulipas Health Authorities expressed their confidence that a success of the Sangui system will help hundreds of thousands of Mexican citizens to find relief from yearlong sufferings and to regain their quality of life. They underlined that also the entire public health system would benefit substantially from implementing an effective system for healing chronic wounds by way of substantial cost savings. Eduardo Mena, CEO of Sanguis BioTech Latino América, said: "Together with our German partners, we have invested heavily to show the Mexican people and its authorities that this major health problem can be tackled successfully. So, we are excited about the opportunity to put the Sangui system to an official test, where we can demonstrate the efficiency of our innovative approach."

Having acted as a co-signatory to the agreement, Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, was impressed by the attention paid to this test by numerous high ranking officials: "Evidently, there is a strong awareness of the benefits to be gained from our wound management system. Our partners at Sangui LA have done a great job to demonstrate its potential and hence to attract the commitment of the Public Health System to actually implement it in case the results are as expected."

29.10.2008

Company News

SanguiBioTech presented wound management products at leading Jordan medical institutions

Witten, Germany, October 29, 2008 - Management and medical staff of SanguiBioTech GmbH held a series of presentations at leading medical institutions in the Kingdom of Jordan in the week of October 20, 2008. Visited were, among others, the central military hospital of the Royal Medicine Services, the headquarters of Jordan Civil Defence, which also directs Jordan's entire emergency rescue system, the King Abdullah University Hospital in Irbid (http://www.kauh.jo/kauh/english/index.aspx), as well as Jordan's largest health center, the Al Basheer Hospital in Amman.

Along with top representatives of the respective hospital managements high ranking surgeons and rescue doctors as well as directors of cardiological, dermatological, oncological and orthopedical departments participated in the meetings which were attended by about 20 to 30 persons each. Introduced were the Chitosan based wound dressings, i.e. the already registered CHITOSKIN dressings as well as the newly developed dressing for surgical applications. Moreover, the presentations extended to the wound healing system for chronic wounds including SCABREMOVE and HEMO2SPRAY. Products and concepts met thorough interest and were intensely discussed among the experts.

The series of presentations had been organized by Abu-Jabir Industrial and Marketing Consulting (www.abu-jabir.com). Besides its headquarters in Amman, Jordan, Abu-Jabir operates subsidiaries in the United Arab Emirates and in Egypt. Sharif Abu-Jabir, founder and president of this enterprise, emphasized: "Since the inception of our close cooperation with Sangui in spring 2007 we have established the basis for widespread business activities in the Arab countries. The current status lets us expect a sound and sustainable demand for Sangui products after having them registered." The distribution partner in Jordan will be the pharmaceuticals trading house Nobles Medical Supplies Company Ltd.

Sangui Managing Director Hubertus Schmelz was impressed by the success of the presentations: "We have had the opportunity to visit large, top modern and excellently equipped hospitals, which influence the wound care system of the entire Kingdom. The positive reactions of the medical experts as well as the highly professional support provided by Abu-Jabir and by its distribution partners give rise to considerable expectations for our future cooperation." It was too early, however, Schmelz added, to prepare a reliable time frame and business plan.

22.10.2008

Company News

Sangui BioTech International, Inc., reports sales decrease, continued losses

Shareholders' Meeting to be held on November 18, 2008

Witten, Germany, October 22, 2008 - Sangui BioTech International, Inc., published its financial statements for its fiscal year ended June 30, 2008, on October 21. According to the report on form 10-KSB as filed with the SEC the company yielded sales of its cosmetics and wound management products in the amount of approximately USD 207,000 a decrease of 44% as compared with sales revenues of approximately USD 372,000 in the previous year. The decrease is attributable to the company's focus on product development (new cosmetics series, new surgical application of Chitoskin wound pads) and a lower return on marketing efforts with respect to cosmetic products. This also entailed higher research and development cost as well as an increase in General and administrative expenses.

The company reports a net loss for the year of approximately USD 854,000 (2007 net loss: approximately USD 721,000). The resulting accumulated deficit amounts to approximately USD 23.3 million. Total shareholders' deficit as of June 30, 2006 stands at approximately USD 1.1 million. Net cash used in operating activities of approximately USD 1.1 million was offset by cash inflows from financing activities (net of effects of exchange rates) in the amount of approximately USD 1.4 million.

Operations in the 2008 financial year were financed by investments from several European investors in the amount of approximately USD 994,000. In accordance with US-GAAP the amount is shown as foreign currency translation adjustments in the profit-and-loss statement.

The company invites its shareholders to attend the General Meeting of Shareholders on November 18, 2008 on the premises of the Forschungs- und Entwicklungszentrum in Witten, Germany.

21.10.2008

Company News

SanguiBioTech GmbH and Fanales GmbH cooperate in marketing and sales of PURE MO2ISTURE cosmetics

Witten, Germany, October 21, 2008 - SanguiBioTech GmbH and Fanales GmbH, Recklinghausen, Germany, intend to cooperate in marketing and sales of PURE MO2ISTURE cosmetics. The agreement to this effect comprises an initial test phase of six months. Under the terms of the mutually non-exclusive agreement, Fanales will sell Sangui's PURE MO2ISTURE cosmetics in a specialized shop in Dusseldorf and strive to establish additional distribution channels. Sangui will deliver the required quantities and provide information and marketing support.

For many years Fanales' Managing Director Hans Wollmann served with Evonik-Degussa, where his most recent position was Director Marketing & Sales of the French subsidiary Rexim S.A. Rexim S.A. being one of the world's leading manufacturers of amino acids, Hans Wollmann has excellent contacts in the global cosmetics industry.

17.09.2008

Company News

Shareholders' meeting delayed
to include FY 2008 report

Witten, Germany, September 17, 2008 - Sangui BioTech International, Inc., is currently preparing its financial statements for its 2008 financial year (ended June 30, 2008). The ensuing report on form 10KSB will be filed with the SEC and made public in due course. It will be included in the proxy materials for the forthcoming annual shareholders' meeting. This was also requested in a letter by the SEC. Subsequently, the shareholders' meeting will be delayed by a few weeks. Shareholders will be informed about the new schedule immediately after the pertaining resolutions will have been passed by the Board of directors.

08.09.2008

Company News

Sangui BioTech International, Inc. files remaining reports;
shareholders' meeting to be held on October 9, 2008

Witten, Germany, September 8, 2008 - On Wednesday, August 27, 2008, Sangui BioTech International, Inc., filed with the SEC its financial statements on Form 10KSB for the 2007 financial year (ended June 30, 2007) as well as the quarterly reports on Forms 10QSB for the quarters ended September 30, 2007, December 31, 2007 as well as March 31, 2008. The company is now current with its SEC filings.

The Board of Directors has set the date for the forthcoming shareholders' meeting at October 9, 2007 at 11 a.m. Central European Time. It will take place in Witten, Germany. The preliminary agenda and proxy statement are available here on the corporate website www.sanguibiotech.com. All documents as well as the date of the meeting are subject to SEC approval, Shareholders will be informed of any changes via the corporate website.

20.06.2008

Company News

Sangui BioTech files three 2007 quarterly reports, sales increased, losses continue

Witten, Germany, June 20, 2008 - Sangui BioTech International, Inc., has now filed its quarterly reports on Form 10QSB with the SEC covering the quarters ended September 30, 2006; December 31, 2006, and March 31, 2007. In the first nine month of its 2007 financial year the company generated sales of approximately USD 345,000 as compared to approximately USD 95,000 in the first nine months of FY 2006. Operating expenses amounted to almost USD 600,000. The increase as compared to the USD 356,000 in the previous year period is due to increased efforts to expand operations to international markets. The company incurred a net loss of approximately USD 486,000. Sangui used cash in operating acitivities of approximately USD 457,000 (2006 period: approximately USD 242,000). The company's accumulated deficit amounted to USD 22.3 million as of March 31, 2007.

Apart from the contribution margin generated from sales of its cosmetics and wound management products, operations in the first nine months of FY 2007 were financed by investments from several European investors in the amount of approximately USD 543,000. In accordance with US-GAAP the amount is shown as Foreign currency translation adjustments in the profit-and-loss statement and as Effect of exchange rate changes in the cash-flow statement respectively.

In the first nine months of its financial year 2008 (July 1, 2007 through March 31, 2008), Sangui BioTech International, Inc., generated hardly any sales. The company invested in identifying and establishing new sales opportunities in international markets, to wit Mexico and the Arab countries, as well as in the approval process of its Hemospray wound spray in accordance with European, Mexican and US regulations. Ensuing losses were financed by continued investments from several European investors.

05.06.2008

Company News

Experts confirm HEMO2SPRAY safety
Sangui submits milestone documentation to Notified Body

Witten, Germany, June 5, 2008 - As a part of the registration of its HEMO2SPRAY wound spray according to the CE standards of the European Union SanguiBioTech GmbH now submitted comprehensive documentation to the Notified Body. Among a broad array of requested documents, this important milestone includes the required independent expert opinions about the toxicological and virological status of the product.

The virological opinion analyses potential risk factors in the raw material and describes the production process with special emphasis on its ability to remove eventually existing virusses from the product or to inactivate the remainders. According to the opinion the high temperature treatment and micro-filtration stages of the production process provide a sufficient safety margin.

After a detailed appreciation of the therapeutical experiences the toxicological opinion concludes that "in view of the expected improvements of wound healing the use of HEMO2SPRAY is a positive element of wound management. Hemoglobin and its degradation products in the intended application form and quantities are safe for patients, staff and third persons. Subsequently, the benefit/risk ratio for HEMO2SPRAY is positive."

The next stage of the registration process consists mainly of the validation of the production process from the generation of the raw material to the end product."

28.05.2008

Company News

HemCon and Sangui joint press release:

HemCon Medical Technologies Leverages Sangui Technology to Expand its Wound Care Products Line

PORTLAND, Ore. - May 28, 2008 - HemCon Medical Technologies Inc. today announced it will use Witten, Germany-based SanguiBioTech GmbH's CHITOSKIN technology platform to help further innovations in hemostatic bandages and wound care dressings for the acute care market.

Under the terms of the agreement, HemCon will leverage Sangui's technology platform to enhance and expand its product offerings for surgical and wound care. HemCon developed the chitosan-based hemostatic HemCon® Bandages and ChitoFlex® dressings that are used by military and medical first responders as well as health care professionals around the globe.

"We explored a wide variety of technology platforms to add to our new surgical and wound care offerings and feel that the Sangui chitosan platform offers great opportunities to enhance our solutions," said John W. Morgan, president and CEO of HemCon. "We're committed to continuing our investment to develop new choices for medical professionals and consumers. This agreement is an important step forward in realizing the full potential of chitosan-based products."

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. Sangui BioTech International focuses on vascular and hemostasis products. The firm specializes in developing oxygen-carrying agents to treat blocked arteries, anemia or acute blood loss through SanguiBioTech GmbH.

"We are proud to enter into an agreement with HemCon and offer our chitosan platform to help innovate new surgical and wound care products," said Sangui Managing Director Hubertus Schmelz. "There is definitely a demand for products that can adapt to specific medical needs, especially as it relates to wound care."

HemCon retains exclusive worldwide market and distributing rights for products developed under this structured financial agreement. HemCon will submit developed products for U.S. approvals to the FDA, while Sangui will prepare documentation for registration in the European Union.

About HemCon Medical Technologies Inc.

HemCon Medical Technologies Inc., founded in 2001, develops, manufactures and markets innovative products and technologies to improve patient care and control infection. The flagship hemostatic HemCon dressings are used by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance. In addition HemCon develops and licenses unique technology platforms and delivery systems for us in the cosmeceutical, wound care, and cardiovascular health markets. Synpart, a wholly-owned, European subsidiary of HemCon is a leading designer and manufacturer of general oral care products. HemCon corporate headquarters reside in Portland, Oregon with additional commercial operations Ireland; England; Germany and the Czech Republic. For more information, please visit www.hemcon.com.

About SanguiBioTech GmbH

SanguiBioTech GmbH is a wholly-owned subsidiary of Sangui BioTech International Inc. (www.pinksheets.com: SGBI). Established in 1995, the company focuses on improving the oxygen supply to the human body. The company has developed a range of products providing oxygen to the healthy as well as to the damaged skin and distributes medicosmetics as well as wound management products in Europe and other international markets. One of its core technologies is the patented Chitoskin technology range, a unique and multi purpose chitosan based wound dressing family.

20.05.2008

Company News

Sangui reports first actual order from Arab countries

Witten, Germany, May 20, 2008 - Future Health Est., based in Jeddah, Saudi Arabia, has now purchased an initial quantity of CHITOSKIN wound dressings, SanguiBioTech GmbH reports today. Future Health Est. is a distributor of various medical and other goods in Saudi Arabia.

Sangui Managing Director Hubertus Schmelz underlines that efforts to enter the Arabian markets had never been interrupted: "Over the past months we have been in constant contact with our Arabian partner. We are very glad that this cooperation now starts to come to fruition. Although there is no commitment yet with regard to future additional orders it is our aim in the medium term to establish an ongoing business relationship."

21.04.2008

Company News

Investors acquire share in Sangui BioTech GmbH

Witten, Germany, April 21, 2008 - A group of German investors is about to acquire up to 10% of the shares of SanguiBioTech GmbH, Witten, for a purchasing price of up to € 750,000. The acquisition will be effectuated by way of a capital increase which will be subscribed to by the investors. It will become effective after the investment sum will have been paid in on a Sangui account and after the capital increase will have been entered in the German register of commercial companies. The majority of those investors are already engaged as shareholders of Sangui BioTech International, Inc., and by subscribing to convertible promissory notes.

Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, said: "We are glad that our investors show uninterrupted confidence in Sangui's future. Their thorough understanding of the long term perspective of our products and projects is highly appreciated. This renewed investment will mainly serve to finance ongoing business as well as special initiatives to promote further development, marketing and sales activities."

08.04.2008

Company News

Sangui BioTech International, Inc., reports sales increase, continued losses

Wolfgang Barnikol resigns from executive positions

Witten, Germany, April 8, 2008 - Sangui BioTech International, Inc., published its financial statements for its fiscal year ended June 30, 2006, on April 3, 2008. According to the report on form 10-KSB as filed with the SEC the company almost tripled its sales of cosmetics and wound management products, although from a low level. In FY 2006, Sangui yielded sales of approximately USD 137,000 and a Gross Profit of approximately USD 19,000. Due to the ongoing cost containment program operating expenses were down 25% to approximately USD 758,000. The company reports a net loss for the year of approximately USD 743,000. The resulting accumulated deficit amounts to approximately USD 21.8 million. Total shareholders' deficit as of June 30, 2006 stands at approximately USD 384,000. Net cash used in operating activities of approximately USD 283,000 was partially offset by cash inflows from financing activities in the amount of approximately USD 235,000.

According to the 10-KSB report these conditions raise substantial doubt about the Company's ability to continue as a going concern. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds. Therefore, the Company is dependent on funds raised through equity or debt offerings.

Preliminary unaudited figures for Sangui's fiscal year ended June 30, 2007, indicate that Sangui yielded sales in this period of approximately USD 373,000. An increase in operating expenses which is attributable to increased marketing and sales efforts is the main factor for the resulting net loss of approximately USD 704,000. The company strives to file its pending quarterly and annual reports for its 2007 and 2008 fiscal years over the next couple of months.

Cornerstones of Sangui's current business include sales of cosmetics and wound management products through different distribution partners in Germany and abroad. Sales in several Arab countries are subject to their registration in the respective countries. Sangui is not involved in these registration procedures and has no influence on them. At present, there is no reliable basis to predict when sales will start and which volumes may be generated. Negotiations about raising a substantial mezzanine loan were now discontinued as conditions appeared to be unfavorable for the company. Further business opportunities are largely dependent on the successful registration of Sangui's Hemospray wound spray. The company's current plans anticipate that the registration for sales in the European Union may be obtained in the course of calendar year 2008.

The company currently has two employees as well as consulting agreements with five persons in charge of management and development acitivities. In the course of the 2007 calendar year several European investors provided cash inflows to the company of more than EUR 0.6 million.

Wolfgang Barnikol resigns from executive positions

Professor Wolfgang Barnikol has declared to lay down his positions as President, Chief Executive Officer and Chief Financial Officer of Sangui BioTech International, Inc.. He will continue to serve as a Member of the Board of the company and contribute his scientific and medical expertise to further promote Sangui projects. The Board of Directors has agreed to appoint Thomas Striepe as interim CEO and Joachim Fleing as interim CFO of Sangui International. Both will serve in this position until the election of a new Board of Directors on the occasion of the planned shareholders' meeting. Operations of the company will continue to be directed by Hubertus Schmelz, the Managing Director of SanguiBioTech GmbH the Witten based wholly-owned subsidiary.

Remark:

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements.
Words such as "anticipates", "expects", "intends", "plans", "believes", "seeks", "estimates" and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.